Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM20B90)

Drug Name
AMT-130 Drug Info
Indication
Disease Entry ICD 11 Status REF
Huntington disease 8A01.10 Phase 1/2 [1]
Cross-matching ID
TTD Drug ID
DM20B90

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Clinical Trial Drug(s)
Download the Complete Related Drug List
Drug(s) Targeting Huntingtin (HTT)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Tominersen DM7ERXY Huntington disease 8A01.10 Phase 3 [2]

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Huntingtin (HTT) TTUKLBM HD_HUMAN Not Available [1]

References

1 ClinicalTrials.gov (NCT05243017) A Phase Ib/II Study to Explore Safety, Tolerability, and Efficacy Signals of Multiple Ascending Doses of Striatally-Administered rAAV5-miHTT Total Huntingtin Gene (HTT) Lowering Therapy (AMT 130) in Early Manifest Huntington's Disease. U.S.National Institutes of Health.
2 Potential disease-modifying therapies for Huntington's disease: lessons learned and future opportunities. Lancet Neurol. 2022 Jul;21(7):645-658.